Abstract 444P
Background
High-dose cytarabine (HDAC) is used to treat hematologic malignancies. Eye disorders are common side effects caused by cytarabine (AraC) being transported from the blood into tear fluid. In our institution, four times a day (FM4) or six times a day (FM6) of 0.1% fluorometholone eye drops are used to prevent AraC-induced eye disorders. In this study, we investigated the prophylactic effects of FM6 or FM4 to prevent AraC-induced eye disorders retrospectively.
Methods
We targeted the patients who were hospitalized and administered with HDAC twice a day at a dose of 1 g/m2 or more between April 2011 and March 2018. The patients received 0.1% fluorometholone eye drops in a both eyes from the start of HDAC dose to 48 hours after the end of HDAC dose. We investigated the incidence of eye disorders or grade based on the medical records from the start of HDAC dose until 7 days after the end of HDAC dose, retrospectively.
Results
There were 36 patients of FM4 and 44 of FM6 for prevention of AraC-induced eye disorders, respectivity. The incidence of eye disorders was 6 (16.7%) in FM4 and 7 (15.9%) in FM6. No Grade 3 eye disorders occurred in both groups. The number of courses of the eye disorder appeared for FM4 and FM6 were 1 and 2 courses. In addition, the median of AraC cumulative dose at the time of the eye disorders appeared for FM4 and FM6 was 10 (4-20) g/m2 and 20 (6-42) g/m2.
Conclusions
There is no difference in preventive effect between FM4 and FM6 for AraC-induced eye disorders. Further, FM4 is considered useful and a convenient method for the prevention of AraC-induced eye disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract